111 related articles for article (PubMed ID: 21905526)
41. ESA payment changes: chasing a moving target.
Sargent JA
Nephrol News Issues; 2008 Jan; 22(1):36-7. PubMed ID: 18271437
[No Abstract] [Full Text] [Related]
42. Erythropoietin therapy in patients with chronic renal failure.
Pinevich AJ; Petersen J
West J Med; 1992 Aug; 157(2):154-7. PubMed ID: 1441466
[TBL] [Abstract][Full Text] [Related]
43. The new architects of health care reform.
Schaeffer LD
Health Aff (Millwood); 2007; 26(6):1557-9. PubMed ID: 17978374
[TBL] [Abstract][Full Text] [Related]
44. First-year Medicare Part D prescription drug benefits: medication access and continuity among dual eligible psychiatric patients.
West JC; Wilk JE; Rae DS; Muszynski IL; Rubio-Stipec M; Alter CL; Sanders KE; Crystal S; Regier DA
J Clin Psychiatry; 2010 Apr; 71(4):400-10. PubMed ID: 19925748
[TBL] [Abstract][Full Text] [Related]
45. Life in the health reform fast lane.
Lipson DJ; Duke KS; Lichiello P; Ginsburg P
Bus Health; 1996 Apr; 14(4):50-4, 56-8, 60-2. PubMed ID: 10157681
[No Abstract] [Full Text] [Related]
46. Keep a watchful eye in '95.
Mills JW
Pa Med; 1995 Jan; 98(1):6. PubMed ID: 7885711
[No Abstract] [Full Text] [Related]
47. Recombinant human erythropoietin in patients with anemia due to end-stage renal disease. US multicenter trials.
Sobota JT
Contrib Nephrol; 1989; 76():166-78; discussion 212-8. PubMed ID: 2684519
[No Abstract] [Full Text] [Related]
48. State health reform.
Mollica RL
Empl Benefits J; 1995 Dec; 20(4):2-9. PubMed ID: 10153604
[TBL] [Abstract][Full Text] [Related]
49. Finding the magic formula for ESA use.
Neumann ME
Nephrol News Issues; 2010 May; 24(6):8. PubMed ID: 20509399
[No Abstract] [Full Text] [Related]
50. The changing tide in ESRD care.
Sullivan JD
Nephrol News Issues; 2010 Jul; 24(8):24, 27-8. PubMed ID: 20695319
[No Abstract] [Full Text] [Related]
51. AWP reimbursement scrutinized by several states.
Carroll J
Manag Care; 2003 Apr; 12(4):11-2. PubMed ID: 12747021
[No Abstract] [Full Text] [Related]
52. Continuous erythropoietin receptor activator (Mircera) for renal anemia.
McGahan L
Issues Emerg Health Technol; 2008 Feb; (113):1-6. PubMed ID: 18354858
[TBL] [Abstract][Full Text] [Related]
53. ESA therapy for anemia management: a call for civil discourse.
McAllister CJ
Nephrol News Issues; 2007 Jun; 21(7):49-50. PubMed ID: 17623986
[No Abstract] [Full Text] [Related]
54. The impact of health reform on health system spending.
Cutler DM; Davis K; Stremikis K
Issue Brief (Commonw Fund); 2010 May; 88():1-14. PubMed ID: 20491172
[TBL] [Abstract][Full Text] [Related]
55. 2009: time sensitive healthcare issues await. SCHIP, Medicaid and Medicare payment reductions on lawmakers' to-do list for the new year.
Ferman JH
Healthc Exec; 2009; 24(1):54-5. PubMed ID: 19601415
[No Abstract] [Full Text] [Related]
56. Beyond economics 101: insights into healthcare reform from the Congressional Budget Office.
Orszag PR
Healthc Financ Manage; 2009 Jan; 63(1):70-5. PubMed ID: 19161033
[No Abstract] [Full Text] [Related]
57. [Erythropoietin in the treatment of anemia in chronic renal insufficiency].
Valderrábano F
An Med Interna; 1991 Jun; 8 Suppl 2():22-3. PubMed ID: 1878467
[No Abstract] [Full Text] [Related]
58. Erythropoietin for the anemia of chronic renal failure.
Schwartz AB; Prior J; Terzian L; Kahn B
Am Fam Physician; 1988 Jun; 37(6):211-5. PubMed ID: 3289343
[No Abstract] [Full Text] [Related]
59. Reconciling decision models with the real world. An application to anaemia of renal failure.
Shih YC; Kauf TL
Pharmacoeconomics; 1999 May; 15(5):481-93. PubMed ID: 10537965
[TBL] [Abstract][Full Text] [Related]
60. Squeezing more cost and care out of dialysis: our patients would pay the price.
Meyer KB; Kassirer JP
Am J Med; 2002 Feb; 112(3):232-4. PubMed ID: 11893351
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
